Earum Pharmaceuticals Ltd - 542724 - Compliance Certificate Relating To Share Transfer Facility As Per Regulation 7(3) Of SEBI (LODR) For The Half Year Ended 31St March, 2022
Compliance Certificate relating to Share Transfer Facility as per Regulation 7(3) of SEBI (LODR) for the half year ended 31st March, 2022 Earum Pharmaceuticals Ltd - 542724 - Board Meeting Intimation for Intimation Of Board Meeting
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/04/2022 ,inter alia, to consider and approve Intimation of Board Meeting Earum Pharmaceuticals Ltd - 542724 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayEarum Pharmaceuticals Ltd 2CINL24230GJ2012PLC071299 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRIYA RAVAL Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: cs@earumpharma.com Name of the Chief Financial Officer: PAYAL PATEL Designation: Chief Financial Officer EmailId: info@earumpharma.com Date: 08/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Earum Pharmaceuticals Ltd - 542724 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018 FOR QUARTER ENDED ON MARCH 31, 2022 Earum Pharmaceuticals Ltd - 542724 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- PRIYA RAVALDesignation :- Company Secretary and Compliance Officer Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Payal B Patel Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth N Patel Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Payal B Patel Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth N Patel